^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AC0176

    i
    Other names: AC-176, AC0176, AC-0176, AC 0176, AC176, AC 176
    Company:
    Accutar Biotech
    Drug class:
    Androgen receptor degrader
    Related drugs:
    4ms
    PROTAC'ing the androgen receptor and other emerging therapeutics in prostate cancer. (PubMed, Expert Rev Anticancer Ther)
    PROTACs, DAARIs, and anitens represent novel and promising AR-targeting therapeutics that may become an important part of prostate cancer treatment in the future. Elucidating mechanisms of resistance, including ability of these agents to target full length AR, may yield further insights into maximal therapeutic efficacy aimed at silencing AR signaling.
    Review • Journal
    |
    AR (Androgen receptor)
    |
    bavdegalutamide (ARV-110) • AC0176 • luxdegalutamide (ARV-766)
    8ms
    A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=28, Terminated, Accutar Biotechnology Inc | Trial completion date: Nov 2024 --> Mar 2024 | Active, not recruiting --> Terminated; Subject benefit-risk ratio changes, sponsor decides to voluntarily terminate study
    Trial completion date • Trial termination • Metastases
    |
    AC0176
    10ms
    A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=8, Terminated, Accutar Biotechnology Inc | Trial completion date: Jan 2026 --> Oct 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2025 --> Oct 2023; Subject benefit-risk ratio changes, sponsor decides to voluntarily terminate study
    Trial completion date • Trial termination • Trial primary completion date • Metastases
    |
    AC0176
    1year
    A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=8, Active, not recruiting, Accutar Biotechnology Inc | Recruiting --> Active, not recruiting | N=150 --> 8
    Enrollment closed • Enrollment change • Metastases
    |
    AC0176
    1year
    A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=36, Active, not recruiting, Accutar Biotechnology Inc | Recruiting --> Active, not recruiting | Trial completion date: Mar 2024 --> Nov 2024 | Trial primary completion date: Mar 2023 --> Apr 2024
    Enrollment closed • Trial completion date • Trial primary completion date • Metastases
    |
    AC0176